A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild-Type Patients

Request Access

Demographics (3)

Disease Events (30)

  • ADJ_PLATINUM - Did patient receive platinum-based therapy in adjuvant setting? (phv00496285.v1.p1)
  • ANY_PRIOR_PLATINUM - Did patient receive any platinum-based therapy in any setting prior to enrollment? (phv00496287.v1.p1)
  • BEST_CHANGE_SLD - Percent change in sum of longest diameter (SLD) tumor measurements by RECIST (phv00496264.v1.p1)
  • BEST_RESPONSE - RECIST classification of best response to talazoparib therapy on trial (phv00496263.v1.p1)
  • DIAGNOSIS_DATE - Date patient was diagnosed with cancer (phv00496277.v1.p1)
  • HAD_PRIOR_ADJ_THERAPY - Adjuvant chemotherapy or hormonal therapy was delivered (phv00496281.v1.p1)
  • HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00496274.v1.p1)
  • HRD_SCORE - Homologous Recombination Deficiency score (phv00496280.v1.p1)
  • HRD_SCORE_METS - Homologous Recombination Deficiency score on metastatic tumor (phv00496266.v1.p1)
  • HRD_SCORE_PRIMARY - Homologous Recombination Deficiency score on primary tumor (phv00496265.v1.p1)
  • HRD_TESTED - Was specimen tested for successfully HRD (phv00496279.v1.p1)
  • IS_TUMOR - Tumor status (phv00496273.v1.p1)
  • METASTATIC_PLATINUM - Did patient receive platinum-based therapy in metastatic setting? (phv00496286.v1.p1)
  • MUTATION - Germline or tumor mutation used for study enrollment (phv00496261.v1.p1)
  • PRIMARY_METASTATIC_TUMOR - Primary tumor, metastasis, or transformed cell line (phv00496275.v1.p1)
  • PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00496276.v1.p1)
  • PRIOR_ADJ_SYSTEMIC_THERAPY_1 - First line of adjuvant therapy delivered (phv00496282.v1.p1)
  • PRIOR_ADJ_SYSTEMIC_THERAPY_2 - Second line of adjuvant therapy delivered (phv00496283.v1.p1)
  • PRIOR_ADJ_SYSTEMIC_THERAPY_3 - Third line of adjuvant therapy delivered (phv00496284.v1.p1)
  • PRIOR_SYSTEMIC_METASTATIC_THERAPY_1 - FIrst line of metastatic therapy delivered (phv00496288.v1.p1)
  • PRIOR_SYSTEMIC_METASTATIC_THERAPY_2 - Second line of metastatic therapy delivered (phv00496289.v1.p1)
  • PRIOR_SYSTEMIC_METASTATIC_THERAPY_3 - Third line of metastatic therapy delivered (phv00496290.v1.p1)
  • PRIOR_SYSTEMIC_METASTATIC_THERAPY_4 - Fourth line of metastatic therapy delivered (phv00496291.v1.p1)
  • PRIOR_SYSTEMIC_METASTATIC_THERAPY_5 - Fifth line of metastatic therapy delivered (phv00496292.v1.p1)
  • PRIOR_SYSTEMIC_METASTATIC_THERAPY_6 - Sixth line of metastatic therapy delivered (phv00496293.v1.p1)
  • PRIOR_SYSTEMIC_METASTATIC_THERAPY_7 - Seventh line of metastatic therapy delivered (phv00496294.v1.p1)
  • PRIOR_SYSTEMIC_METASTATIC_THERAPY_8 - Eight line of metastatic therapy delivered (phv00496295.v1.p1)
  • TIME_TO_RESPONSE - Time to response on trial therapy (phv00496268.v1.p1)
  • TTP - Time to progression on trial therapy (phv00496267.v1.p1)
  • TUMOR_TYPE - Tissue of origin of tumor (phv00496262.v1.p1)

Race and Ethnicity (1)

Other (9)